Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE
Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE
Active, not recruiting · NCT06015230 · Registry updated 2024-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 1 / Phase 2 | 2024-09-25 | NCT06015230 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 14 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking union Medical Hosipital | Beijing | China | 1 |